Table 1.
N = 72 | |
---|---|
Age (years) | 24 ± 5 |
Parity | 1 (0–2) |
Gestational age of pregnant participantsa | 16 (11–25) |
Body mass index (BMI) | 29 8 |
Public health insurance | 47 (65%) |
Ethnicity | |
Non-Hispanic, Black/African American | 60 (83%) |
Hispanic, non-Black | 1 (1%) |
Less than a high school education | 47 (65%) |
Age of sexual debut (years) | 16 (15–17) |
Number of reported lifetime sexual partners | 5 (3–8) |
History of abnormal cervical cancer screening | 22 (31%) |
Current tobacco use | 13 (18%) |
History of a sexually transmitted infection(s) (STI) | 47 (65%) |
Bacterial vaginosis at enrollment | 25 (35%) |
An additional STI at enrollment | 12 (17%) |
Trichomonas vaginalis | 8 (11%) |
Neisseria gonorrhoeae | 5 (7%) |
Reported provision of expedited partner therapy | 42 (58%) |
Days followed until a negative chlamydia NAAT | 12 (7–20) |
Late submission of chlamydia NAATb | 25 (35%) |
Lost to follow upc | 13 (18%) |
Gestational age of pregnant participants is reported as the weeks of gestation during which participants received initial treatment for chlamydial infection.
Late submission of chlamydia NAAT was defined as submission of a NAAT test >10 days following treatment or last study appointment.
Lost to follow up was defined as failure to complete the study by returning to submit chlamydia NAATs until a negative result returned within the study period post-treatment. Means are reported with standard deviation (±) and medians are reported with interquartile ranges (IQR).